An excerpt from Mool’s published research
OneSource Specialty Pharma Inc.
NSE: ONESOURCE · Report 27 Oct 2026
Business model and financial foundation
OneSource (NSE: ONESOURCE), Pharmaceutical CDMO (biologics, drug-device combinations, sterile injectables, softgels): revenue of ₹1,422 crore in FY26 (-1.6% on FY25), an EBITDA margin of 21.4%, net profit of ₹-73.8 crore and net debt of ₹1,176 crore.
Read the analysis and its sources- Revenue, FY26 (₹ crore)
- 1,422
- consolidated
- Revenue growth, FY26
- -1.6%
- on FY25
- EBITDA margin, FY26
- 21.4%
- EBITDA (Company EBITDA, excluding other income and exceptional items) / revenue
The figures retain the periods and comparisons stated in the analysis. This excerpt describes the business; full research access is explained above.